Skip to content

Revvity RVTY Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$208.29M-41.0%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Illumina logo
IlluminaILMN
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Veeva Systems logo
Veeva SystemsVEEV
IQVIA logo
IQVIAIQV

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's payments for repurchase of common stock?
Revvity (RVTY) reported payments for repurchase of common stock of $86.5M in Q1 2026.
How has Revvity's payments for repurchase of common stock changed year-over-year?
Revvity's payments for repurchase of common stock decreased by 43.7% year-over-year, from $153.59M to $86.5M.
What is the long-term trend for Revvity's payments for repurchase of common stock?
Over 4 years (2021 to 2025), Revvity's payments for repurchase of common stock has grown at a 83.1% compound annual growth rate (CAGR), from $73.07M to $820.82M.